Page 9 - மருந்து வைத்திருத்தல் நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Biohaven Acquires Kleo Pharmaceuticals And Licenses Platform Technology From Yale University To Form Biohaven Labs - Acquires full ownership of Kleo Pharmaceuticals with two novel immune modulating platforms: the Multi-targeted Antibody Therapy Enhancer (MATE™) conjugation platform and Antibody Recruiting Molecule (ARM™) platform - Enters into exclusive license agreement with Yale University for the development and commercialization of Yale s extracellular target degrader platform based on intellectual property derived from ground-breaking research in the laboratory of Professor David Spiegel - Establishes Biohaven Labs at Science Park in New Haven to advance these three novel discovery platforms and several existing discovery partnerships to serve as an integrated chemistry and discovery research engine to complement Biohaven s late-stage clinical development and commercial expertise

New havenUnited statesYale universityDonnie mcgrathPatrick reidPatrickc reidDavida spiegelBusiness development contactExchange commission onDrug administrationDavid spiegel at yale universityKleo pharmaceuticals acquisitionBiohaven therapeutics ltdProfessor david spiegel at yale universityBiohaven pharmaceutical holding company ltdKleo pharmaceuticals